The method of treatment of chronic dermatoses
(57) Abstract:The invention relates to medicine, namely to dermatology, and can be used in the treatment of eczema and psoriasis. To do this, as a therapeutic agent using a synthetic analogue of the hormone of the pineal gland - melaxen at a dose of 0.5-1.5 mg, before a night's sleep, oral, within 7-20 days. The method simplifies the treatment, reducing treatment time of recurrence and extending remission of the disease. table 2., 1 Il. The invention relates to medicine, namely to dermatology, and can be used in the treatment of eczema and psoriasis.The difficulty of treating these diseases resistant chronic course and a tendency to relapse, due to their etiopathogenesis.Work in recent years has identified the importance and place neiroallergicescoe immunological, metabolic changes in the body of patients with eczema (Kubanova A. A. and others journal of dermatology. 1985. - 8. C. 16-19; Smashin et al. Materials for the study of pathogenesis and therapy of patients with eczema and atopic dermatitis. Regional scientific-practical conference of dermatovenereologists. Proc. Dokl. Orenburg, 1994. C. 10.; Lobanovsky, N., Kravchenko, L. A. Journal of dermatology, cosmetology and saxop the skin, in particular, the predominance of inhibitory processes in the cerebral cortex, and therefore, apparently, eczema occupies a Central place in the structure of skin diseases in the elderly (Belousova T. L. proceedings of the 4th all-Russian Congress of dermatovenereologists. Krasnodar 1976. - S. 128-129, N. Kochergin.G. c et al. PATOLOGOANATOMICHESKOE mechanisms of atopic dermatitis. The honey. Ref. W. - 1987. - 8. - C. 6-10.; Antoniev D. A., prokhorenkov Century Century journal of dermatology. 1995. - 2. - S. 20-22).Researchers also attracts the immune system in the pathogenesis of eczema. The examined patients were identified immunodeficiency, flowing with a Hyper-reactive T-system and the immune system. Statistically significant reduction in the number of subpopulations of lymphocytes, whereas the generation of suppressor remains at a normal level. This is particularly evident in elderly patients (Abidov M M and others journal of dermatology. 1982. - 2. - S. 33-36; Danilov, A. A. and other abstracts. Dokl. - Dnepropetrovsk, 1991. - S. 63; Novikov, M., Ivashkevich, L. Proc. Dokl., Ekaterinburg, 1994. S. 68-69).Recently actively developing methods of treatment of chronic dermatoses with their etiopathogenesis: using antihistamin the external therapy (Antoniev A. A. and other journal of dermatology. - 1982. - 5. - S. 12-14; Shotmaster I. J., Shimanov N. A. Journal of dermatology. - 1998. - 2. - S. 27-31; Samsonov Century A. and others journal of dermatology. - 1998. - 4. - S. 48-50).There is a method of treatment of atopic dermatitis, including the study of the immune status of the patient and decreasing the relative numbers of T-lymphocytes, increased IgG and IgM, decreased IgA - introduction ascorbic acid and levamisole, alternating doses of their medication within 3 weeks (RF Patent 1638852, a 61 K 39/00, 27.09.95, BI 27).The method allows to reduce time of treatment of children with atopic dermatitis, lengthen remission of the disease, reduces the number of complications and recurrence. The disadvantage of this method is its duration and complexity.There is a method of treatment of psoriasis, which involves the study of the patient's immune status and the violation of T-suppressor in T-helper cells, intramuscular injection, 2 times a day to enter dalargin within 5-10 days and with the lack of normalization of immune status - repetition rate (A. C. the USSR 1821217 AND 61 TO 37/02, 15.06.93, BI 22).However, the known methods of treatment are not effective enough, difficult to implement, time-consuming, do not reduce the tendency to relapse, because no is). In addition, many drugs are called side effects.The objective of the invention is the search for remedies, corrective simultaneously endocrine, immune and other systems.The technical result in the implementation of the invention is manifested in the simplification of the treatment and the shortening of the time, the elongation magnetizing period that has an economic effect.This technical result is achieved by the fact that as a therapeutic agent using a synthetic analogue of the hormone of the pineal gland, synthesized from amino acids of plant origin, at a dose of 0.5-1.5 mg, before a night's sleep, oral, within 7-20 days.Well-known commercial product, a synthetic analogue of the hormone of the pineal gland - melaxen, melatonin (manufacturer of Melanin, USA) (RLS - Dr. M., 1999, S. 600-601).Pharmaceutical drug - adaptogenic, contributes to the organization of the biological rhythm of the body and normalization of sleep a night. Stimulates cellular and humoral immunity, regulates neuroendocrine function.Melatonin has anti-stress effect, due to its influence on neurotransmitter with mechanisms (Kumar M. S. Chen, C. Z., Sharp D. C. et al. Diurnal Huctuation melatonin in enkephalin levels in the hypothalamus and preoptic areas of the die male rat: Effects of pinealectomy//Neuroendocrinology. - 1982. - Vol. 35. - P. - 28-32).Acting simultaneously on the neuroendocrine and the immune system, melatonin optimizes homeostasis and protects against stress (Maestroni J. Melatonin and the immune system//Melatonin and the Pincal Gland. - Paris, - 1992. - P. 59).The drawing shows the location of opioid peptides (light arrows) in vzaimootnosheniah between the epiphysis (black arrows - the effect of melatonin), Central nervous, endocrine and immune systems in the process of forming the stress response (Clinical medicine, 12, 1998, S. 49).Indications of use are sleep disorders, adaptation of the body when changing external factors.Studies on the use of melatonin has allowed to establish its favorable impact on the normalization of the status of T cells, the thymus gland (Walter Pierpaoli William Reason. The miracle of melatonin. M, Binomial, 1997, S. 111).The recommended dosage of melatonin increases depending on age 0.5-1 mg at the age of 40-44 years up to 3.5-5 mg 75 years and over.The stated set of characteristics provides technical result, because the outline is due by considering biological rhythms in the body, since it is known that melatonin produced in the pineal gland at night. The dose received funds from 0.5 to 1.5 mg within 7-20 days adjusted according not from age, but from the severity of the disease, is necessary and sufficient to achieve a technical result, with the exception of side effects.The feasibility of the proposed method is illustrated by specific examples of its use on patients.Example 1. Patient M., 70, was admitted to the hospital with a diagnosis of microbial eczema of the right lower limb, complicated allegedly, lymphadenitis.Sick 3 years. The process is difficult, compounded 3-5 times per year, the normal duration of remission 2-3 months. Exacerbation of skin lesions are common, differing in haste to therapy. Comorbidities: chronic gastritis, colitis. Hypertension stage 2.Regarding the previous exacerbations were treated in hospital and outpatient domiciliary traditional means without effect, and was hospitalized in clinical regional dermatovenerologic dispensary.Upon receipt pathologically on the right foot and lower leg the skin was dramatically swollen, infiltrated and hyperemic, against this background, it was noted coarse lamellar desquamation, exudative scales. The margins are clear, on the periphery of the expression screenings papular and erosive lesions. A similar rash absently located on the skin of the upper extremities and torso, more on the back.Total blood biochemical parameters were without abnormalities.The patient was prescribed treatment with melatonin 0.5 mg at night for 10 days. Topically to the lesions cream Uns.The result is a passable treatment on day 3 the itching stopped, rash on the trunk and upper extremities disappeared. To 5 days the main focus on the left foot and Shin decreased. Peeling lesions ceased to 9 days of treatment, all lesions regressed to 11 days.Clinical remission lasted 11 months and increased in comparison with the usual timing 3 times.Example 2. Patient K., 41 year was admitted to the hospital with a diagnosis of common krupnooptovyj psoriasis in the stationary phase.Sick 12 years. The process is difficult, compounded up to 5 times per year, the normal duration of remission 2-3 months. Acute skin% the ology: hypertension 2 degrees, cholecystitis.Regarding the previous exacerbations were treated in hospital and ambulatory traditional means, the effect is negligible, and therefore was re-hospitalized.Upon receipt of the pathological process was widespread. On the scalp, trunk, extremities localized many large papular elements a bright pink color. On the trunk there was a continuous lesion covering the skin of the back, waist, chest and abdomen. On the entire surface of the foci was significantly expressed silvery white peeling.The patient was prescribed treatment with melatonin 0.5 mg at night for 10 days on the background of external treatment cream Uns.The result of the treatment on day 3 pockets turned pale, for 5 days decreased infiltration, on the 7th day on the body in the field of solid lesion appeared the areas of healthy skin. Peeling lesions ceased to 10 days of treatment. Fully lesions regressed to 13 days.Clinical remission lasted 9 months and increased in comparison with the usual timing 3 times.In terms of the Stavropol regional dermatovenerologic di the disease in age from 36 to 82 years. Comparative data on treatment results of the inventive and conventional methods are shown in tables 1, 2.Comparative data treatment the traditional method and melatonin are presented in table 1 for eczema in table 2 by psoriasis.Thus, using the proposed method provides a significant increase in the effectiveness of treatment of chronic dermatoses, reducing material costs by lengthening the period of remission and reduce the time of stay of patients in hospital and can be recommended in clinical practice. Method for the treatment of eczema or psoriasis, characterized in that the injected oral synthetic analogue of melatonin melaxen at a dose of 0.5-1.5 mg before a night's sleep within 7-20 days.
FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to pharmaceutical composition for intranasal administration contains zolmitriptan that is agonist of 5-HT1-receptor and pharmaceutically acceptable carrier. The composition has pH value less 6.0. The composition can be used for treatment of migraine and related disorders. The composition shows the improved stability in storage and provides effective relief for patients suffering with migraine.
EFFECT: improved and valuable medicinal properties of composition.
11 cl, 1 tbl, 9 ex
FIELD: medicine, veterinary science.
SUBSTANCE: it is suggested to apply indometophen known previously as a radioprotector. It has been established that application of indometophen at different terms within the first 4 d after irradiation helps to increase survival rate and affect positively the flow of reparative processes in the body at no side effects.
EFFECT: higher efficiency of therapy.
FIELD: medicine, gastroenterology, pharmacy.
SUBSTANCE: invention relates to a pharmaceutical composition used in treatment of changed gastroenteric contracting capability. The composition comprises tegaserod and co-agent taken among the group including prucaloprid, fluoxetine, fedotosine, baclofen, octreotide, omeprazol and ranitidine. The combination provides attainment of synergetic effect.
EFFECT: improved and valuable medicinal properties of composition.
7 cl, 3 ex
FIELD: pharmaceutical technology, pharmacy.
SUBSTANCE: invention relates to producing solid combined medicinal formulations of preparations showing the hypotensive effect on both systolic and diastolic arterial blood pressure, increasing the cardiac blood ejection and enhancing the tolerance to physical loading. Proposed medicinal agent comprises the following components, wt.-%: perindopril erbumin, 0.6-6.6; indapamide, 0.1-2.1; microcrystalline cellulose, 16.0-35.0; magnesium stearate, 0.3-1.7; aerosil, 0.2-1.0; croscarmelose sodium, 1.1-7.5, and lactose, the balance. Also, invention discloses a method for preparing the medicinal formulation. Invention provides reducing mechanical losses of perindopril erbumin and indapamide in the process of the formulation preparing, retaining their properties in intact state and enhancing biological availability of active substances.
EFFECT: improved and enhanced medicinal and pharmaceutical properties of agent.
3 cl, 2 tbl, 2 ex
FIELD: organic chemistry, medicine, oncology.
SUBSTANCE: invention proposes using derivatives of N-substituted indole-3-glyoxylamide of the formula (1) as an antitumor medicinal agent and/or agent inhibiting angiogenesis (variants), and an antitumor medicinal agent (variants). The claimed derivatives are known as immunomodulating agents. Invention revealed both an antitumor activity of indicated compounds, among them, under conditions for arising the medicinal resistance (cytotoxic effect) and their inhibitory effect on angiogenesis. This allows using these compounds in treatment of tumors including leukemia and metastasizing carcinoma, or in treatment of other diseases wherein the suppression of angiogenesis is required (for example, in wound healing).
EFFECT: valuable medicinal properties of agent.
13 cl, 9 dwg
FIELD: medicine, pharmaceutical industry.
SUBSTANCE: invention relates to production of solid pharmaceutical agents enhancing excretive kidney function useful in treatment of hypertension and chronic heart failure, accompanying with retention of sodium and water in organism. Claimed pelleted pharmaceutical composition comprises core, containing (mass %) inapamide 0.8-1.0; lactobiose 51-30; polyvinylpyrrolidone 1-3; microcrystalline cellulose 20-30; starch glycolate 3-10; magnesium stearate 0.1-1.04 and stomach soluble shell containing (mass %): oxypropylcellulose 25-40; vinylpyrrolidone-vinylacetate copolymer 25-40; titania 20-30; and talc 10-20. Method for production of such composition also is disclosed.
EFFECT: pelleted pharmaceutical composition of high active ingredient solubility without losses of tablet stability.
7 cl, 1 tbl, 3 ex
FIELD: medicine, ophthalmology.
SUBSTANCE: one should introduce 10 ml 0.1%-serotonin adipinate twice daily for 10 d parenterally. The innovation enables to achieve rapid resorption of blood in ocular cavity after the hemorrhage occurred due to deblocking serotonin receptors against hemoglobin that provides normalization of microcirculation in choroidea and retina along with reconstructing inflow-outflow of intraocular liquid in ocular cavity.
EFFECT: higher efficiency of therapy.
2 cl, 2 ex
FIELD: medicine, chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention proposes a composition possessing anti-hypertensive and diuretic activity with prolonged release of an active component. The composition comprises an envelope-covered core comprising indapamide as an active component and ludipress, hydroxypropylmethylcellulose, aerosil and stearate as accessory components. The core is covered by a film-forming envelope that is based on hydroxypropylmethylcellulose preferably and comprising additionally polyethylene glycol, glycerol, talc, titanium dioxide and lactose. Method for preparing the novel composition involves mixing indapamide and accessory components followed by forming the prepared mixture to form the core of required configuration and size and applying the envelope. The composition is characterized by continuous release of indapamide, high fracture and abrasion strength, stability of active component during storage with the fitness time above 2 years.
EFFECT: improved preparing method, improved and valuable properties of composition.
9 cl, 2 tbl, 4 ex